Abstract
e14563 Background: Tumor-specific neoantigens are considered as personalized and potential ultimate targets for cancer immunotherapy. Recently, neoantigen cancer vaccines have been designed to train the patient's immune system to specifically target and kill tumor cells. However, the safety and efficacy of neoantigen vaccines in pancreatic cancer treatment remain poorly understood. Methods: Personalized peptide neoantigen cancer vaccines were successfully designed and manufactured for pancreatic cancers with low tumor mutation burden. Seven patients with advanced pancreatic cancer refractory to standard treatments were enrolled and treated with personalized peptide neoantigen vaccine, iNeo-Vac-P01. Besides the evaluation of the safety and clinical efficacy of iNeo-Vac- P01, pre- and post-vaccination peripheral blood samples were collected to analyze the vaccine’s immunogenicity. Results: For all 7 patients, none sever vaccine-related adverse effects was witnessed. The mean progression free survival, overall survival (OS) and OS associated with vaccine treatment were 3.1, 24.1 and 8.3 months, respectively. For Patient P01, who had a 21-month OS associated with vaccine treatment, the abundance of the TCR clone remarkably increased after vaccination, indicating the potential of iNeo-Vac-P01 to specifically induce a subset of T cells to kill tumor cells. This study also demonstrated that the quantity of IFN-γ in peripheral blood might be a potential biomarker for OS. Conclusions: We believed that it was the first tentative study focused in the application of peptide-based neoantigen cancer vaccine in advanced pancreatic cancer. Promisingly, personalized peptide neoantigen vaccine might provide a new strategy to improve the limited clinical efficacy for pancreatic cancer. Clinical trial information: NCT03645148.
Highlights
Tumor-specific neoantigens are considered as personalized and potential ultimate targets for cancer immunotherapy
We believed that it was the first tentative study focused in the application of peptide-based neoantigen cancer vaccine in advanced pancreatic cancer
From January 1, 2018 to March 31, 2020, a total of 7 patients with advanced pancreatic cancer were enrolled in the trial to receive iNeo-Vac-P01
Summary
Tumor-specific neoantigens are considered as personalized and potential ultimate targets for cancer immunotherapy. Neoantigen cancer vaccines have been designed to train the patient's immune system to target and kill tumor cells. The safety and efficacy of neoantigen vaccines in pancreatic cancer treatment remain poorly understood. Many patients are diagnosed with advanced tumors[2] Even for those initially diagnosed in a very early state and received standard treatments such as surgical resection combined with systemic radiotherapy or chemotherapy, their 5-year OS rate has not yet exceeded 25%(3). The incidence of pancreatic cancer is increasing worldwide. To resolve the contradiction between the lack of effective treatments for pancreatic cancer and its increasing incidence, greater efforts should be directed to the development of more promising therapies
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
